626 related articles for article (PubMed ID: 19758222)
21. B cells in rheumatoid arthritis: from hypothesis to the clinic.
Keystone EC
Rheumatology (Oxford); 2005 May; 44 Suppl 2():ii8-ii12. PubMed ID: 15851525
[TBL] [Abstract][Full Text] [Related]
22. [Rituximab (MabThera) as treatment of active rheumatoid arthritis].
El Fassi D; Nielsen CH; Bendtzen K
Ugeskr Laeger; 2006 Nov; 168(47):4079-81. PubMed ID: 17134602
[TBL] [Abstract][Full Text] [Related]
23. Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis.
Vos K; Thurlings RM; Wijbrandts CA; van Schaardenburg D; Gerlag DM; Tak PP
Arthritis Rheum; 2007 Mar; 56(3):772-8. PubMed ID: 17328049
[TBL] [Abstract][Full Text] [Related]
24. Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation.
Teng YK; Levarht EW; Toes RE; Huizinga TW; van Laar JM
Ann Rheum Dis; 2009 Jun; 68(6):1011-6. PubMed ID: 18647852
[TBL] [Abstract][Full Text] [Related]
25. B cells as a therapeutic target in autoimmune diseases other than rheumatoid arthritis.
Looney RJ
Rheumatology (Oxford); 2005 May; 44 Suppl 2():ii13-ii17. PubMed ID: 15851522
[TBL] [Abstract][Full Text] [Related]
26. Rituximab fixed retreatment versus on-demand retreatment in refractory rheumatoid arthritis: comparison of two B cell depleting treatment strategies.
Teng YK; Tekstra J; Breedveld FC; Lafeber F; Bijlsma JW; van Laar JM
Ann Rheum Dis; 2009 Jun; 68(6):1075-7. PubMed ID: 19435725
[No Abstract] [Full Text] [Related]
27. [Biopharmaceuticals in the treatment of rheumatoid arthritis].
Baslund B; Bendtzen K
Ugeskr Laeger; 2008 Jun; 170(24):2108-10. PubMed ID: 18572481
[TBL] [Abstract][Full Text] [Related]
28. [The humoral response in rheumatoid arthritis and the effect of B-cell depleting therapy].
Thurlings RM; Vos K; Gerlag DM; Tak PP
Ned Tijdschr Geneeskd; 2006 Jul; 150(30):1657-61. PubMed ID: 16922350
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of B cell depletion in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor alpha agents: an open-label observational study.
Brulhart L; Ciurea A; Finckh A; Notter A; Waldburger JM; Kyburz D; Gabay C
Ann Rheum Dis; 2006 Sep; 65(9):1255-7. PubMed ID: 16540545
[No Abstract] [Full Text] [Related]
30. Anti-CD20 antibody rituximab in the treatment of rheumatoid arthritis.
Korhonen R; Moilanen E
Basic Clin Pharmacol Toxicol; 2010 Jan; 106(1):13-21. PubMed ID: 19686542
[TBL] [Abstract][Full Text] [Related]
31. Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment.
Roll P; Dörner T; Tony HP
Arthritis Rheum; 2008 Jun; 58(6):1566-75. PubMed ID: 18512772
[TBL] [Abstract][Full Text] [Related]
32. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis.
Leandro MJ; Cambridge G; Ehrenstein MR; Edwards JC
Arthritis Rheum; 2006 Feb; 54(2):613-20. PubMed ID: 16447239
[TBL] [Abstract][Full Text] [Related]
33. Clinical outcome and B cell depletion in patients with rheumatoid arthritis receiving rituximab monotherapy in comparison with patients receiving concomitant methotrexate.
Owczarczyk K; Hellmann M; Fliedner G; Röhrs T; Maizus K; Passon D; Hallek M; Rubbert A
Ann Rheum Dis; 2008 Nov; 67(11):1648-9. PubMed ID: 18854518
[No Abstract] [Full Text] [Related]
34. Treatment of rheumatoid arthritis in the 21st century: targeting B-lymphocytes.
Brezinschek HP; Brickmann K; Yazdani-Biuki B; Dörner T; Graninger WB; Brezinschek RI
Wien Med Wochenschr; 2006 Jan; 156(1-2):61-7. PubMed ID: 16465615
[TBL] [Abstract][Full Text] [Related]
35. Panel discussion on B cells and rituximab: mechanistic aspects, efficacy and safety in rheumatoid arthritis and non-Hodgkin's lymphoma.
Panayi GS; Hainsworth JD; Looney RJ; Keystone EC
Rheumatology (Oxford); 2005 May; 44 Suppl 2():ii18-ii20. PubMed ID: 15851523
[TBL] [Abstract][Full Text] [Related]
36. Induction of complete and sustained remission of rheumatoid pachymeningitis by rituximab.
Schmid L; Müller M; Treumann T; Arnold W; Möller B; Aeberli D; Villiger PM
Arthritis Rheum; 2009 Jun; 60(6):1632-4. PubMed ID: 19479865
[TBL] [Abstract][Full Text] [Related]
37. Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response.
Breedveld F; Agarwal S; Yin M; Ren S; Li NF; Shaw TM; Davies BE
J Clin Pharmacol; 2007 Sep; 47(9):1119-28. PubMed ID: 17766699
[TBL] [Abstract][Full Text] [Related]
38. Rheumatoid arthritis: beyond tumor necrosis factor-alpha antagonists, B cell depletion, and T cell blockade.
Manadan AM; Block JA
Am J Ther; 2008; 15(1):53-8. PubMed ID: 18223354
[TBL] [Abstract][Full Text] [Related]
39. TRU-015, a fusion protein derived from an anti-CD20 antibody, for the treatment of rheumatoid arthritis.
Rubbert-Roth A
Curr Opin Mol Ther; 2010 Feb; 12(1):115-23. PubMed ID: 20140823
[TBL] [Abstract][Full Text] [Related]
40. Modulation of molecular imprints in the antigen-experienced B cell repertoire by rituximab.
Palanichamy A; Roll P; Theiss R; Dörner T; Tony HP
Arthritis Rheum; 2008 Dec; 58(12):3665-74. PubMed ID: 19035487
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]